SC
ROIV icon

Stempoint Capital’s Roivant Sciences ROIV Stock Holding History

Stempoint Capital’s Portfolio ROIV Stock Details ROIV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-915,000
Closed -$618K – 98
2025
Q2 		$618K Buy
+915,000
New +$9.92M 0.2% 50

Other funds holding ROIV

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
QF
QVT Financial New York $1.7B AUM 173.77% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

Stempoint Capital's ROIV Position: Q2 2026 in Review

Stempoint Capital reduced its Roivant Sciences (ROIV) stake by 9.7% in Q2 2026, selling an estimated $1.1M and leaving 348,408 shares worth $12.3M. The position accounts for 2.12% of the portfolio, ranked #16.

Stempoint Capital first reported a position in ROIV in Q4 2023 and has held it in 11 quarters since. The position peaked at $63.5M in Q3 2025. 499 funds tracked by Wall St. Rank hold ROIV as of Q2 2026.

  • Stempoint Capital held 348,408 shares of Roivant Sciences worth $12.3M as of Q2 2026.
  • Stempoint Capital sold 37,392 Roivant Sciences shares in Q2 2026, an estimated $1.1M.
  • Roivant Sciences made up 2.12% of Stempoint Capital's portfolio in Q2 2026, its #16 holding.
  • Stempoint Capital first reported a position in Roivant Sciences in Q4 2023 and has held it in 11 quarters since.
  • Stempoint Capital's Roivant Sciences position peaked at $63.5M in Q3 2025.
  • 499 funds tracked by Wall St. Rank held Roivant Sciences as of Q2 2026.

Based on Stempoint Capital's 13F filing for Q2 2026, filed 14 Aug 2026.